Binding constructs and methods for use thereof
    3.
    发明申请
    Binding constructs and methods for use thereof 有权
    结合结构及其使用方法

    公开(公告)号:US20050136049A1

    公开(公告)日:2005-06-23

    申请号:US10627556

    申请日:2003-07-26

    摘要: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

    摘要翻译: 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白,其特征在于一种同源结构的结合域,例如抗原,反向受体等,野生型IgG1,IGA或IgE铰链作用区,即IgE CH2, 区域多肽或具有零个,一个或两个半胱氨酸残基和免疫球蛋白CH2和CH3结构域的突变IgG1铰链区多肽,并且能够产生ADCC和/或CDC,同时主要作为其形成二硫键的能力受损的多肽 链接的多聚体。 可以以高表达水平重组产生融合蛋白。 还提供了相关的组合物和方法,包括融合蛋白的细胞表面形式和融合蛋白的免疫治疗应用以及编码这种融合蛋白的多核苷酸。

    DNA vaccines encoding antigen linked to a domain that binds CD40
    9.
    发明申请
    DNA vaccines encoding antigen linked to a domain that binds CD40 审中-公开
    编码与结合CD40的结构域连接的抗原的DNA疫苗

    公开(公告)号:US20070025982A1

    公开(公告)日:2007-02-01

    申请号:US11542423

    申请日:2006-10-03

    IPC分类号: A61K39/395 A61K39/12

    摘要: Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto MHC molecules. T cells specific for the peptide antigens are activated, leading to an enhanced immune response. The vaccine may comprise antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid encoding antigen(s) linked to a domain that binds at least one receptor. A preferred embodiment of the invention targets HIV-1 env antigen to the CD40 receptor, resulting in delivery of antigen to CD40 positive cells, and selective activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.

    摘要翻译: 将一种或多种抗原靶向细胞表面受体的疫苗可改善抗原特异性体液和细胞免疫应答。 与结合细胞表面受体的结构域连接的抗原被内化,将抗原携带到细胞内隔室中,其中抗原被消化成肽并加载到MHC分子上。 对肽抗原特异性的T细胞被激活,导致增强的免疫应答。 疫苗可以包含连接到结合至少一种受体的结构域的抗原或编码与结合至少一种受体的结构域连接的抗原的DNA质粒。 本发明的优选实施方案将HIV-1 env抗原靶向CD40受体,导致抗原递送至CD40阳性细胞,以及将呈递HIV-1 env抗原的细胞上的CD40受体选择性激活至T细胞。